When tested using in vitro assays, the most encouraging compound promotes the differentiation of AML cells in patient-derived with IDH1 R132H, but not in IDH1 wild-type AML cells, confirming on-target activity in the primary cell setting. This evidence concerns the gene IDH1 and acute myeloid leukemia.